Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials.
Adenosine Monophosphate
/ analogs & derivatives
Alanine
/ analogs & derivatives
Antimetabolites
/ therapeutic use
Antiviral Agents
/ therapeutic use
Betacoronavirus
/ drug effects
COVID-19
Coronavirus Infections
/ diagnosis
Disease Progression
Drug Administration Schedule
Humans
Pandemics
Pneumonia, Viral
/ diagnosis
Randomized Controlled Trials as Topic
SARS-CoV-2
Severity of Illness Index
Survival Analysis
Treatment Outcome
COVID-19
Remdesivir
Journal
Virus research
ISSN: 1872-7492
Titre abrégé: Virus Res
Pays: Netherlands
ID NLM: 8410979
Informations de publication
Date de publication:
15 10 2020
15 10 2020
Historique:
received:
08
07
2020
accepted:
03
08
2020
pubmed:
23
8
2020
medline:
8
10
2020
entrez:
23
8
2020
Statut:
ppublish
Résumé
Several randomized controlled trials (RCTs) were conducted to investigate the effect of remdesivir for patients with COVID-19, but their results were conflicting. Thus, we conducted a network meta-analysis comparing the rate of clinical improvement among patients with COVID-19 who received 5-day course of remdesivir versus 10-day course of remdesivir versus standard care. Our network meta-analysis of 4 randomized controlled trials demonstrated that the rate of clinical improvement was significantly higher in the 5-day remdesivir group and 10-day remdesivir group compared to standard care group (OR [95% confidence interval [CI]] =1.89 [1.40-2.56], P <0.001, OR [95% CI] =1.38 [1.15-1.66], P <0.001, respectively). In addition, the rate of clinical improvement was significantly higher in the 5-day remdesivir group compared to the 10-day remdesivir group (OR [95% confidence interval [CI]] =1.37 [1.01-1.85], P =0.041). Our analysis demonstrated that the use of remdesivir for patients with COVID-19 was associated with the significantly higher clinical improvement rate compared with standard care alone.
Identifiants
pubmed: 32827627
pii: S0168-1702(20)31044-3
doi: 10.1016/j.virusres.2020.198137
pmc: PMC7437510
pii:
doi:
Substances chimiques
Antimetabolites
0
Antiviral Agents
0
remdesivir
3QKI37EEHE
Adenosine Monophosphate
415SHH325A
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
198137Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Références
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659436
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
N Engl J Med. 2020 Nov 5;383(19):1827-1837
pubmed: 32459919
PLoS One. 2014 Dec 26;9(12):e115065
pubmed: 25541687
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440